CTEC.L · LSE · Healthcare
Convatec Group PLC
Also onConsensus Drift
Implied value per share
GBp 186.81
Market price
GBp 214.00
Implied upside
-12.7%
5-year forecast · Perpetuity growth terminal value · Mid-year discounting · Base case · USD model at 0.7466
Value Per Share
Same forecast, different terminal treatment. Percentages vs price.
Forecast Cashflows
Reporting currency (USD). Outflows negative.
| Line | FY26 | FY27 | FY28 | FY29 | FY30 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | USD 2.6bn | USD 2.7bn | USD 2.9bn | USD 3.0bn | USD 3.2bn | +5.6% |
| EBIT | USD 343.6m | USD 362.8m | USD 383.0m | USD 404.4m | USD 426.9m | +5.6% |
| NOPAT | USD 265.4m | USD 280.2m | USD 295.8m | USD 312.3m | USD 329.7m | +5.6% |
| Add depreciation & amortisation | USD 250.8m | USD 264.8m | USD 279.6m | USD 295.2m | USD 311.6m | +5.6% |
| Less capital expenditure | USD -166.8m | USD -176.1m | USD -185.9m | USD -196.2m | USD -207.2m | +5.6% |
| Less increase in working capital | USD -8.2m | USD -8.6m | USD -9.1m | USD -9.6m | USD -10.2m | +5.6% |
| Free cashflow to firm | USD 341.2m | USD 360.3m | USD 380.4m | USD 401.6m | USD 424.0m | +5.6% |
| Discount factor | 0.9639 | 0.8956 | 0.8322 | 0.7732 | 0.7185 | - |
| Present value | USD 328.9m | USD 322.7m | USD 316.5m | USD 310.5m | USD 304.6m | -1.9% |
| Present Value Of The Forecast | USD 1.6bn | |||||
Discount Rate
Source shown per component. All overridable above.
| Risk-free rate | 4.50% | GBP assumption - no free live source available for this market (assumption) |
| Equity risk premium | 5.50% | Market assumption |
| Beta | 0.843 | Reported 0.765, pulled toward 1.0 (Blume) |
| Cost of equity | 9.13% | Risk-free + beta x equity risk premium |
| Cost of debt | 4.56% | Interest expense / average total debt |
| Market capitalisation | USD 4.1bn | 73.1% of capital |
| Total debt | USD 1.5bn | 26.9% of capital, book value as a proxy |
| Tax rate | 22.8% | Effective, capped at statutory |
| WACC | 7.62% | E/V x Re + D/V x Rd x (1 - t) |
Terminal Value
Perpetuity growth is intrinsic. The exit multiple defaults to the company's current EV/EBITDA, so it answers a different question - what the shares are worth if today's rating holds and EBITDA grows as forecast.
Perpetuity growth at 2.50%
76% of EV
- Forecast FCFF, final year
- USD 424.0m
- Capex at depreciation, working capital in reinvestment
- USD 499.8m
- Less reinvestment at g/ROIC (31.0% of NOPAT)
- USD -154.9m
- Capitalised
- USD 344.9m
- ROIC (reported)
- 8.1%
- Terminal value, undiscounted
- USD 6.9bn
- Terminal value, discounted
- USD 5.0bn
- Enterprise value
- USD 6.5bn
- Less net debt
- USD 1.4bn
- Equity value
- USD 5.1bn
Exit at 9.1x EBITDA
75% of EV
- Terminal value, undiscounted
- USD 6.8bn
- Terminal value, discounted
- USD 4.9bn
- Enterprise value
- USD 6.4bn
- Less net debt
- USD 1.4bn
- Equity value
- USD 5.0bn
Spread between methods: 2%.
Sensitivity
Value per share (USD) by discount rate and long-run growth.
| Long-run growth | |||||
|---|---|---|---|---|---|
| Discount rate | 1.50% | 2.00% | 2.50% | 3.00% | 3.50% |
| 5.62% | 3.95 | 4.17 | 4.45 | 4.84 | 5.40 |
| 6.62% | 3.05 | 3.14 | 3.24 | 3.37 | 3.54 |
| 7.62% | 2.45 | 2.47 | 2.50 | 2.53 | 2.57 |
| 8.62% | 2.04 | 2.05 | 2.06 | 2.07 | 2.08 |
| 9.62% | 1.74 | 1.75 | 1.76 | 1.77 | 1.78 |
Outlined: this model. Green text: above today's price of 2.87. Shading: distance from this model's own value.
Priced In
What each input would have to be to justify the current price, one at a time.
| Input | Model | Implied | Gap |
|---|---|---|---|
| Revenue growth, every year | 5.6% | 8.2% | +2.6pp |
| EBIT margin | 13.3% | 15.5% | +2.2pp |
| Discount rate | 7.6% | 7.1% | -0.5pp |
Live formulas, not pasted numbers - edit a driver and the workbook reprices.
Yahoo Finance and RBA data. General information, not advice. Methodology.